Cassava Sciences appoints Freda Nassif as Chief Commercial Officer, enhancing its strategy ahead of Phase 3 trial results for Alzheimer's treatment.Quiver AI SummaryCassava Sciences has appointed Freda...
Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...
This Bull Put strategy has a 76.9% chance of profiting, with a low risk/reward ratio!
Small-caps, which are relatively more sensitive to the vagaries of the economic environment, are playing catchup with their larger counterparts.
Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting...
Cassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential.
Cassava Sciences SAVA has agreed to pay a $40 million fine to settle charges from the U.S. Securities and Exchange Commission (SEC) over allegedly misleading statements about the results of its 2020 mid-stage...